The somatostatin analogs octreotide and lanreotide bind preferentially to SSTR2 (but also to SSTR3 and SSTR5) and are the mainstay in the treatment of acromegaly [7]; however, they have shown a lack of efficacy in NFPA [8]. The gene discussed is SSTR2; the disease is non-functioning pituitary adenoma.